Last reviewed · How we verify
NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 trial testing TG-1801 in CLL in 21 participants. Terminated before completion.
12 June 2024
Quick facts
| Lead sponsor | TG Therapeutics, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 28 April 2021 |
| Primary completion | 12 June 2024 |
| Estimated completion | 12 June 2024 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- TG-1801 — full drug profile →
- Ublituximab — full drug profile →
Conditions studied
- CLL — all drugs for CLL →
- SLL — all drugs for SLL →
- Richter's Transformation — all drugs for Richter's Transformation →
- Indolent Lymphoma — all drugs for Indolent Lymphoma →
Sponsor
TG Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with CLL or SLL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04806035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TG-1801
Trials testing the same drug.
- NCT03804996 — Study of TG-1801 in Subjects With B-Cell Lymphoma · Phase 1 · completed
Other recruiting trials for CLL
Currently open trials in the same condition.
- NCT07120633 — Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL · NA · recruiting
- NCT07108998 — Study of Epcoritamab as a Consolidation Therapy in CLL/SLL · Phase 2 · recruiting
- NCT06846671 — A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lympho · Phase 3 · recruiting
- NCT06506643 — Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms · Phase 1, PHASE2 · recruiting
- NCT05869279 — Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia · Phase 1, PHASE2 · recruiting
Other TG Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT07220252 — Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis · Phase 2, PHASE3 · not yet recruiting
- NCT07503873 — A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection · Phase 2 · not yet recruiting
- NCT07211633 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ub · Phase 3 · recruiting
- NCT06680037 — A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders · Phase 1 · recruiting
- NCT06433752 — A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Mult · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04806035 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TG Therapeutics, Inc.
- Last refreshed: 31 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04806035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing